Investor SentimentCompany will face investor concerns regarding credibility and cannot rule out a potential scenario of restructuring and a strategy shift.
Legal ChallengesThe U.S. District Court for the District of New Jersey ruled that patent #11,033,495 ('495) on Exparel is invalid.
Market CompetitionWith now a path for generics to enter the market, a substantial decline in Pacira’s top and bottomline is expected, and no clear path for recovery is seen.